Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to ...

Prostate cancer and other cancers characterized by “cold” tumors could become more responsive to checkpoint blockade if UBA1 is inhibited.

A study from the University of Michigan Health Rogel Cancer Center may have—at last—cracked the cold case of immunotherapy ...

Many cancer drugs are antimetabolites, which interfere with the cellular processes necessary for tumor growth and survival.

A recent study reveals that immunosuppression, or reduced immune response, in prostate cancer is associated with a ...

Stressing your muscles through exercise strengthens them, and transient stress on cells can prompt them to a response that ...

Cancer cells impair monocyte-mediated T-cell activation by disrupting inflammatory pathways in the tumor microenvironment.

Donisi, C, Pretta, A, Pusceddu, V, Ziranu, P, Lai, E, Puzzoni, M, Mariani, S, Massa, E, Madeddu, C and Scartozzi, M (2024) ...

University of Michigan researchers identified UBA1 as a key player in immunotherapy resistance. Inhibiting UBA1 boosts T-cell ...

Study uses spatial transcriptomics to map intratumoral heterogeneity and microenvironmental dynamics in triple-negative ...

A recent study by a team of researchers at Vanderbilt University found that response to radiation therapy for triple negative ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies ...